Takeda Canada announced that Health Canada has granted market authorization for FRUZAQLA. This medication is indicated for adult patients with metastatic colorectal cancer who either have undergone treatment with standard therapies or are not suitable candidates for such therapies. The standard treatments include chemotherapy based on fluoropyrimidine, oxaliplatin, and irinotecan, alongside an anti-VEGF agent, an anti-EGFR agent, and either trifluridine-tipiracil or regorafenib.
The approval is supported by data from two extensive Phase 3 trials: the multi-regional FRESCO-2 trial and the FRESCO trial conducted in China.
